Medical School · Year 3 · Internal Medicine · includes a discussion video

Seminar 17: Venous Thromboembolism

Internal Medicine Clerkship

Learning Objectives

By the end of this seminar, students will be able to:

1. Identify and stratify risk factors for venous thromboembolism using Virchow's triad and inherited thrombophilia screening criteria
2. Apply the Wells clinical prediction rules to estimate pretest probability of deep vein thrombosis and pulmonary embolism
3. Outline the stepwise diagnostic approach to DVT and PE including appropriate use of D-dimer, compression ultrasonography, and CT pulmonary angiography
4. Select and initiate appropriate anticoagulation therapy based on clinical context, including direct oral anticoagulants and parenteral agents
5. Manage pulmonary embolism across the severity spectrum from low-risk outpatient cases to massive PE requiring thrombolysis
6. Determine appropriate duration of anticoagulation therapy and apply VTE prophylaxis guidelines for medical and surgical patients

Seminar Outline

Section 1: Overview and Risk Factors

Venous thromboembolism encompasses two closely related manifestations of intravascular thrombus formation within the venous system: deep vein thrombosis, which involves clot formation most commonly in the deep veins of the lower extremities, and pulmonary embolism, which occurs when a thrombus embolizes to the pulmonary arterial vasculature. VTE is classified as provoked when an identifiable transient risk factor such as recent surgery or immobilization is present, or unprovoked when no clear precipitant can be identified. This distinction carries profound implications for the duration of anticoagulation therapy and the risk of recurrence. VTE affects approximately 1 to 2 per 1000 adults annually and represents the third most common cardiovascular disease after myocardial infarction and stroke, making it an essential topic for clinical practice.

The pathophysiology of venous thrombosis is elegantly captured by Virchow's triad, which identifies three fundamental predisposing conditions that interact to promote clot formation. Venous stasis, the first component, occurs with immobility from hospitalization, paralysis, prolonged travel, or venous obstruction, allowing activated clotting factors to accumulate and reach concentrations sufficient to overwhelm natural anticoagulant mechanisms. Endothelial injury, the second component, exposes subendothelial collagen and tissue factor, initiating the coagulation cascade, and is caused by surgery, trauma, central venous catheter placement, or inflammatory vessel damage. Hypercoagulability, the third component, encompasses both inherited thrombophilias such as Factor V Leiden and acquired prothrombotic states such as malignancy and antiphospholipid syndrome. In most patients who develop VTE, two or more elements of the triad coexist, creating a cumulative thrombotic risk that exceeds any single factor.

Risk factors for VTE span a wide spectrum of acquired and inherited conditions that can be stratified by the magnitude of risk they confer. Strong acquired risk factors include recent major surgery, particularly orthopedic and cancer-related procedures, hospitalization with immobility, active malignancy, and major trauma. Moderate risk factors include oral contraceptive use, hormone replacement therapy, pregnancy and the postpartum period, and obesity. The inherited thrombophilias contribute variable risk depending on the specific mutation. Factor V Leiden, the most common inherited thrombophilia in Caucasian populations, increases VTE risk 3- to 8-fold in heterozygotes and up to 80-fold in homozygotes. The prothrombin G20210A mutation confers a 2- to 3-fold increased risk. Deficiencies of the natural anticoagulant proteins including protein C, protein S, and antithrombin are less common but carry higher per-event risk.

Thrombophilia testing is a frequently misapplied clinical tool that should be reserved for specific clinical scenarios where the results will change management. Testing is most appropriate in patients with unprovoked VTE at a young age, recurrent VTE, VTE at unusual sites such as cerebral or splanchnic veins, a strong family history of VTE, and recurrent pregnancy loss suggesting antiphospholipid syndrome. Factor V Leiden is found in approximately 20% of unselected VTE patients, and prothrombin G20210A in approximately 6%. Protein C and S deficiency each account for 3 to 5% of cases, while antithrombin deficiency is found in 1 to 2%. Antiphospholipid syndrome, an acquired thrombophilia characterized by antiphospholipid antibodies and clinical thrombosis or pregnancy morbidity, is found in 5 to 10% of VTE patients and is the only thrombophilia for which identification clearly changes the choice of long-term anticoagulant, as warfarin is preferred over direct oral anticoagulants.

<image>Panel A: Diagram of Virchow's triad showing the three overlapping circles of stasis, endothelial injury, and hypercoagulability with clinical examples in each intersection zone. Panel B: Risk factor stratification pyramid showing strong, moderate, and weak risk factors for VTE with relative risk estimates. Panel C: Flowchart for thrombophilia testing indications showing clinical scenarios that warrant testing versus those where testing is not recommended. Panel D: Summary of inherited thrombophilias showing Factor V Leiden, prothrombin mutation, protein C/S deficiency, and antithrombin deficiency with their prevalence in VTE populations and relative risk magnitudes.</image>

Section 2: Deep Vein Thrombosis

The clinical presentation of deep vein thrombosis characteristically involves unilateral lower extremity symptoms, though the clinical features are neither sensitive nor specific enough to confirm or exclude the diagnosis without objective testing. Unilateral leg swelling is the most common presenting complaint and results from venous outflow obstruction by the thrombus. Pain and tenderness along the distribution of the deep venous system, warmth over the affected area, and erythema of the overlying skin are frequently present but variably expressed. The Homans sign, dorsiflexion-induced calf pain, was historically taught as a bedside diagnostic maneuver but has been shown to be unreliable with poor sensitivity and specificity, and its use is no longer recommended. A palpable venous cord, representing a thrombosed superficial or deep vein, is an uncommon but more specific finding. The differential diagnosis of unilateral leg swelling includes cellulitis, Baker cyst rupture, musculoskeletal injury, lymphedema, and chronic venous insufficiency.

The Wells score for DVT is a validated clinical prediction rule that integrates clinical findings and risk factors to estimate the pretest probability of deep vein thrombosis and guide the diagnostic pathway. The score assigns one point each for active cancer, paralysis or recent lower extremity casting, bedridden status for more than 3 days or surgery within the past 12 weeks, localized tenderness along the deep venous system, entire leg swelling, calf swelling exceeding the contralateral leg by more than 3 centimeters, pitting edema, and collateral superficial veins. One additional point is given for previously documented DVT. Critically, two points are subtracted if an alternative diagnosis is considered as likely or more likely than DVT. The resulting score stratifies patients into low probability (0 or fewer points, approximately 5% prevalence), moderate probability (1 to 2 points, approximately 25% prevalence), and high probability (3 or more points, approximately 50% prevalence).

The diagnostic algorithm for DVT uses the Wells score to determine whether D-dimer testing or direct imaging is the appropriate next step. In patients with low pretest probability, a negative D-dimer effectively excludes DVT with a negative predictive value exceeding 99%, and no further testing is required. In patients with moderate pretest probability, either D-dimer testing or compression ultrasonography can serve as the initial diagnostic test. In patients with high pretest probability, compression ultrasonography should be performed directly because the D-dimer has insufficient negative predictive value in this population to safely exclude DVT even when negative. Compression ultrasonography is the imaging modality of choice, demonstrating non-compressibility of the vein at the site of thrombosis with a sensitivity and specificity exceeding 95% for proximal DVT, though sensitivity is lower for isolated calf vein thrombosis.

When the initial compression ultrasound is negative but clinical suspicion remains high, a repeat ultrasound in one week is recommended to detect propagation of a distal thrombus into the proximal venous system, which occurs in approximately 15 to 25% of isolated calf DVTs. D-dimer testing has high sensitivity but low specificity for VTE, and false-positive results are common in elderly patients, hospitalized patients, postoperative patients, patients with malignancy, and pregnant women, limiting its utility as a standalone test. Age-adjusted D-dimer thresholds, using a cutoff of the patient's age multiplied by 10 for patients over 50, have been validated to improve specificity while maintaining sensitivity in older adults. Upper extremity DVT, although less common, is increasingly recognized in the setting of central venous catheters and pacemaker leads and is diagnosed by compression ultrasonography of the upper extremity venous system.

<image>Panel A: Anatomical diagram of the lower extremity deep venous system showing common sites of DVT formation in the iliac, femoral, popliteal, and calf veins with relative frequency. Panel B: Wells score calculation worksheet for DVT showing all nine criteria with point values and the three risk categories with corresponding DVT probability percentages. Panel C: Diagnostic algorithm flowchart beginning with Wells score stratification and progressing through D-dimer testing and compression ultrasonography with decision points and outcomes. Panel D: Ultrasound images demonstrating normal venous compressibility versus non-compressible vein with intraluminal thrombus representing a positive DVT study.</image>

Section 3: Pulmonary Embolism Presentation

Pulmonary embolism presents with a wide spectrum of clinical manifestations ranging from subtle and easily overlooked symptoms to acute cardiovascular collapse, making a high index of clinical suspicion essential for timely diagnosis. Dyspnea is the most common presenting symptom, occurring in approximately 80% of patients, and may be acute in onset or develop gradually over hours to days. Pleuritic chest pain, present in approximately 50% of cases, results from irritation of the visceral pleura by distal emboli that cause pulmonary infarction. Cough occurs in about 20% of patients, hemoptysis in about 10%, and syncope in approximately 10%, with the latter suggesting hemodynamically significant obstruction of the pulmonary vascular bed. The protean nature of PE presentation means that many patients present with nonspecific symptoms, and the diagnosis must be considered in any patient with unexplained dyspnea, chest pain, or hemodynamic instability.

Physical examination findings in pulmonary embolism are often subtle and nonspecific but may provide important diagnostic clues when integrated with the clinical history. Tachypnea is the most common physical finding, followed by tachycardia. Hypoxia is present in many cases but may be absent, particularly in young patients with small emboli and adequate cardiopulmonary reserve. Signs of concurrent DVT, including unilateral leg swelling, are found in approximately 30% of patients with confirmed PE. Jugular venous distension indicates right heart strain from acute increases in pulmonary vascular resistance and may be accompanied by a right ventricular heave or accentuated pulmonic component of the second heart sound. Hypotension with systolic blood pressure below 90 mmHg defines massive PE and indicates critical obstruction of the pulmonary vascular bed with right ventricular failure, representing a medical emergency with high short-term mortality.

The Wells score for PE is a distinct clinical prediction rule from the DVT version that assigns weighted point values to seven clinical criteria to estimate the pretest probability of pulmonary embolism. Clinical signs and symptoms of DVT and the clinical judgment that PE is the most likely diagnosis each receive 3 points, making these the most heavily weighted criteria. Heart rate exceeding 100 beats per minute and immobilization or surgery within the preceding 4 weeks each receive 1.5 points. Previous history of VTE receives 1.5 points, hemoptysis receives 1 point, and active malignancy treated within the past 6 months or currently receiving palliative care receives 1 point. The scoring system can be applied using either a three-tier stratification with low, moderate, and high probability categories or a simplified two-tier system dividing patients into PE unlikely (4 or fewer points) and PE likely (more than 4 points).

The Wells score stratification directly determines the subsequent diagnostic approach and is most useful when applied systematically at the point of initial clinical assessment. A score exceeding 6 places the patient in the high probability category with an estimated PE prevalence of approximately 65%, warranting direct imaging without D-dimer testing. A score of 2 to 6 corresponds to moderate probability with a PE prevalence of approximately 25%, and a score below 2 indicates low probability with a prevalence of approximately 10%. In patients with low or moderate probability, a negative D-dimer can safely exclude PE, while a positive D-dimer or high probability score should prompt CT pulmonary angiography. The ability to accurately stratify patients is critical because indiscriminate imaging leads to unnecessary radiation exposure, incidental findings requiring follow-up, and overdiagnosis of clinically insignificant subsegmental emboli.

<image>Panel A: Clinical presentation spectrum of pulmonary embolism showing symptom frequencies including dyspnea, pleuritic chest pain, cough, hemoptysis, and syncope arranged by decreasing prevalence. Panel B: Physical examination findings in PE with tachypnea, tachycardia, hypoxia, concurrent DVT signs, JVD, and hypotension with their clinical significance. Panel C: Wells score for PE calculation chart showing all seven criteria with their point values and the three-tier probability stratification. Panel D: Two-tier versus three-tier Wells scoring comparison showing PE unlikely versus likely categories alongside low, moderate, and high probability groupings with corresponding PE prevalence.</image>

Section 4: Pulmonary Embolism Diagnosis

The D-dimer is a fibrin degradation product that serves as a highly sensitive but nonspecific biomarker for the presence of intravascular thrombosis and thrombolysis. Its primary diagnostic value lies in its ability to rule out VTE when negative in patients with low to moderate pretest probability, owing to its high sensitivity exceeding 95%. However, D-dimer is elevated in numerous conditions including advanced age, pregnancy, malignancy, infection, inflammation, recent surgery, and hospitalization, resulting in a high rate of false-positive results that diminishes its specificity. Age-adjusted D-dimer thresholds, calculated as the patient's age multiplied by 10 ng/mL for patients over 50, have been prospectively validated to improve specificity by 10 to 15% while maintaining equivalent safety. D-dimer should not be ordered in patients with high pretest probability because even a negative result is insufficient to safely exclude VTE, and it adds no value in patients already receiving therapeutic anticoagulation.

The Pulmonary Embolism Rule-out Criteria, known as the PERC rule, represents a clinical decision tool designed to identify patients with such low probability of PE that no further testing, including D-dimer, is warranted. All eight criteria must be met to apply the rule: age under 50 years, heart rate under 100 beats per minute, oxygen saturation above 94% on room air, no unilateral leg swelling, no hemoptysis, no surgery or trauma within the past 4 weeks, no prior DVT or PE, and no estrogen use. The PERC rule should only be applied when the clinical gestalt places the patient in the low pretest probability category, as its safety has not been validated in moderate or high probability populations. When all PERC criteria are met in a low-probability patient, the rate of missed PE is below 2%, which is considered acceptable given the risks of further testing including radiation exposure, contrast nephropathy, and false-positive findings.

CT pulmonary angiography has become the gold standard imaging modality for the diagnosis of pulmonary embolism, offering rapid acquisition, high spatial resolution, and the ability to directly visualize thrombus within the pulmonary arterial vasculature. Modern multidetector CT scanners achieve sensitivity and specificity exceeding 95% for PE and can simultaneously evaluate for alternative diagnoses that may explain the patient's symptoms. Ventilation-perfusion scintigraphy remains a valuable alternative for patients with contraindications to CT-PA, including severe contrast allergy and advanced chronic kidney disease with an estimated glomerular filtration rate below 30 mL/min. Compression ultrasonography of the lower extremities may be performed when the diagnosis of PE is uncertain, as identification of a proximal DVT in a patient with symptoms suggestive of PE confirms VTE and initiates anticoagulation therapy. Bedside echocardiography is not a primary diagnostic tool but can demonstrate right ventricular dysfunction that supports the diagnosis in hemodynamically unstable patients in whom transport to CT is unsafe.

The diagnostic algorithm for pulmonary embolism integrates pretest probability assessment with sequential testing to maximize diagnostic accuracy while minimizing unnecessary imaging. In patients with low pretest probability who meet all PERC criteria, no further testing is needed. In patients with low or moderate pretest probability who do not meet PERC criteria, a negative D-dimer safely excludes PE. In patients with a positive D-dimer or high pretest probability, CT pulmonary angiography is the definitive imaging study. In the hemodynamically unstable patient with suspected massive PE, bedside echocardiography demonstrating right ventricular dilation and dysfunction provides sufficient diagnostic support to initiate empiric anticoagulation or thrombolysis while arrangements for definitive imaging are made. This stepwise approach ensures that diagnostic resources are directed appropriately and that life-threatening PE is neither missed nor its treatment inappropriately delayed.

<image>Panel A: D-dimer sensitivity and specificity diagram showing the concept of high sensitivity for ruling out VTE with list of conditions causing false-positive elevations. Panel B: PERC rule checklist showing all eight criteria that must be met with the clinical context requirement of low pretest probability and the safety threshold of less than 2% missed PE. Panel C: CT pulmonary angiography images showing normal pulmonary arterial opacification versus filling defects representing acute pulmonary emboli in the main and lobar pulmonary arteries. Panel D: Comprehensive PE diagnostic algorithm flowchart from pretest probability assessment through PERC, D-dimer, and CT-PA with decision points and management outcomes at each step.</image>

Section 5: PE Severity Assessment

Risk stratification of pulmonary embolism is essential because it directly determines the intensity of treatment, the level of monitoring required, and the disposition of the patient. Massive PE, defined by sustained systemic arterial hypotension with systolic blood pressure below 90 mmHg for more than 15 minutes, pulselessness, or persistent profound bradycardia with heart rate below 40, represents the most severe category and carries a short-term mortality rate of 25 to 50%. Submassive PE describes hemodynamically stable patients who demonstrate evidence of right ventricular dysfunction on imaging or elevated cardiac biomarkers, indicating significant hemodynamic compromise that has not yet progressed to overt shock. Low-risk PE encompasses hemodynamically stable patients without evidence of right ventricular dysfunction or biomarker elevation, who have the best prognosis and may be candidates for outpatient management. This three-tier classification guides the therapeutic approach from standard anticoagulation to systemic thrombolysis.

Multiple biomarkers and imaging findings serve as indicators of PE severity and help identify patients at risk for clinical deterioration. Right ventricular dilation on CT-PA, defined as an RV to LV diameter ratio exceeding 1.0, indicates significant right heart strain from acute increases in pulmonary vascular resistance. Echocardiographic findings of right ventricular dysfunction include McConnell's sign, which describes regional wall motion abnormality with akinesis of the right ventricular free wall and preserved apical contractility. Cardiac troponin elevation reflects myocardial strain from right ventricular pressure overload and ischemia, while elevated B-type natriuretic peptide indicates right ventricular volume overload and wall stress. Serum lactate elevation suggests tissue hypoperfusion and is associated with increased mortality. The combination of imaging findings and biomarker elevation identifies patients at highest risk for hemodynamic deterioration who may benefit from escalated therapy.

The Pulmonary Embolism Severity Index is a validated prognostic scoring system that estimates 30-day mortality risk using readily available clinical and demographic variables. The original PESI score assigns points based on age (1 point per year), male sex (10 points), cancer (30 points), heart failure (10 points), chronic lung disease (10 points), heart rate of 110 or above (20 points), systolic blood pressure below 100 (30 points), respiratory rate of 30 or above (20 points), temperature below 36 degrees Celsius (20 points), altered mental status (60 points), and oxygen saturation below 90% (20 points). The score classifies patients into five risk classes: class I (65 points or fewer, very low risk with 1.6% mortality) through class V (more than 125 points, very high risk with 10 to 25% mortality). PESI classes I and II identify patients who may be suitable for early discharge or outpatient management.

The simplified PESI score was developed to improve the clinical usability of the original PESI by reducing it to six equally weighted binary variables, each contributing one point. These variables include age over 80 years, active cancer, chronic cardiopulmonary disease, heart rate of 110 beats per minute or above, systolic blood pressure below 100 mmHg, and oxygen saturation below 90%. A simplified PESI score of 0 identifies low-risk patients with a 30-day mortality of approximately 1%, who are candidates for outpatient treatment if they have adequate social support, access to follow-up care, and no other conditions requiring hospitalization. A score of 1 or more indicates higher risk and generally warrants inpatient management. The simplified PESI has been shown to perform comparably to the original PESI in identifying low-risk patients and is now widely used due to its ease of application at the bedside without complex point calculations.

<image>Panel A: Three-tier PE severity classification showing massive, submassive, and low-risk categories with their hemodynamic definitions, mortality rates, and treatment implications. Panel B: Imaging and biomarker severity indicators including RV/LV ratio on CT, McConnell sign on echocardiography, troponin elevation, BNP elevation, and lactate levels with their prognostic significance. Panel C: Original PESI scoring table showing all eleven variables with their point values and the five risk classes with corresponding 30-day mortality percentages. Panel D: Simplified PESI calculation showing the six binary variables and the two-tier risk stratification with criteria for outpatient management eligibility.</image>

Section 6: Anticoagulation Therapy

Initial anticoagulation for venous thromboembolism has undergone a paradigm shift with the advent of direct oral anticoagulants, which have largely replaced the traditional approach of parenteral heparin bridging to warfarin. Apixaban and rivaroxaban are the preferred first-line agents for most patients with VTE because they can be initiated without a lead-in period of parenteral anticoagulation, simplifying the treatment pathway and facilitating outpatient management. Low-molecular-weight heparin, most commonly enoxaparin and dalteparin, remains the preferred initial agent for patients who require parenteral anticoagulation, such as those with severe renal impairment or those being considered for thrombolytic therapy. Unfractionated heparin administered by continuous intravenous infusion is reserved for patients at high bleeding risk who may need rapid reversal, patients with severe renal failure, and hemodynamically unstable patients who may require thrombolysis or surgical intervention. Fondaparinux, a synthetic factor Xa inhibitor, serves as an alternative parenteral agent for patients with a history of heparin-induced thrombocytopenia.

The dosing regimens of direct oral anticoagulants for VTE treatment follow specific protocols that must be carefully followed to ensure adequate initial anticoagulation intensity. Apixaban is initiated at 10 mg twice daily for the first 7 days, followed by a maintenance dose of 5 mg twice daily, with no requirement for preceding parenteral anticoagulation. Rivaroxaban follows a similar upfront loading approach with 15 mg twice daily for the first 21 days, then transitioning to 20 mg once daily for maintenance. In contrast, edoxaban and dabigatran require at least 5 days of initial parenteral anticoagulation before transitioning to oral therapy, with edoxaban dosed at 60 mg once daily and dabigatran at 150 mg twice daily. This distinction between DOACs that require parenteral lead-in and those that do not is clinically critical and determines whether a patient can be managed entirely as an outpatient from the time of diagnosis.

The traditional warfarin-based treatment approach, though now considered second-line for most VTE patients, remains relevant for specific populations and requires understanding of the bridging protocol. Parenteral anticoagulation with LMWH or UFH is initiated immediately upon diagnosis, and warfarin is started concurrently on day one. Warfarin is a vitamin K antagonist that depletes clotting factors II, VII, IX, and X, but because it also depletes the natural anticoagulant proteins C and S more rapidly, there is a transient prothrombotic state during the first several days of therapy that necessitates overlap with a parenteral agent. The parenteral anticoagulant is continued for a minimum of 5 days and until the INR has been at or above 2.0 for at least 24 hours. The target INR range is 2.0 to 3.0 for most VTE indications. Warfarin requires frequent INR monitoring, has numerous food and drug interactions, and carries a higher bleeding risk relative to DOACs, which explains the shift in first-line recommendations.

Certain clinical situations preclude the use of anticoagulation therapy and require alternative approaches to VTE management. Active major hemorrhage is an absolute contraindication to anticoagulation, and an inferior vena cava filter should be placed to prevent migration of existing thrombus to the pulmonary vasculature. Recent intracranial hemorrhage similarly contraindicates anticoagulation, though the optimal timing for initiating or resuming anticoagulation after intracranial bleeding remains an area of active debate. Severe thrombocytopenia requires a case-by-case assessment balancing the thrombotic risk of VTE against the bleeding risk of anticoagulation. In patients with massive PE and hemodynamic instability, the primary therapeutic consideration shifts from anticoagulation alone to systemic thrombolysis, which can rapidly restore pulmonary blood flow and reverse right ventricular failure. The decision to employ thrombolysis must weigh the significant bleeding risk, including a 2 to 3% risk of intracranial hemorrhage, against the life-threatening nature of massive PE.

<image>Panel A: Comparison chart of initial anticoagulation options for VTE showing DOACs, LMWH, UFH, and fondaparinux with their indications, advantages, and limitations. Panel B: DOAC dosing timeline diagrams for apixaban and rivaroxaban showing upfront loading protocols versus edoxaban and dabigatran showing required parenteral lead-in periods. Panel C: Warfarin bridging protocol timeline showing simultaneous initiation of parenteral anticoagulant and warfarin with the overlap period and INR monitoring milestones. Panel D: Flowchart for anticoagulation contraindications showing active bleeding, intracranial hemorrhage, and severe thrombocytopenia with alternative management strategies including IVC filter placement and thrombolysis considerations.</image>

Section 7: Specific PE Scenarios

Massive pulmonary embolism presents as a hemodynamic emergency characterized by sustained hypotension, obstructive shock, or cardiac arrest resulting from acute right ventricular failure due to the sudden increase in pulmonary vascular resistance. The primary treatment for massive PE is systemic thrombolysis, most commonly with alteplase administered as 100 mg intravenously over 2 hours, which rapidly dissolves pulmonary arterial thrombus and restores right ventricular function. The decision to administer thrombolysis must account for the significant bleeding risk, including absolute contraindications such as active internal bleeding, recent intracranial surgery or stroke within 3 months, and structural intracranial disease. When systemic thrombolysis is contraindicated, surgical pulmonary embolectomy provides a direct approach to clot removal and is performed at specialized centers with cardiothoracic surgery capability. Catheter-directed therapy, including catheter-directed thrombolysis and mechanical thrombectomy, offers an intermediate approach that delivers lower doses of thrombolytic agent directly to the clot, potentially reducing systemic bleeding complications. Extracorporeal membrane oxygenation may serve as a bridge therapy in patients with refractory cardiogenic shock.

Submassive pulmonary embolism occupies a clinical middle ground between massive PE and low-risk PE, defined by hemodynamic stability in the presence of right ventricular dysfunction on imaging or elevated cardiac biomarkers. The standard treatment is therapeutic anticoagulation with close hemodynamic monitoring, typically in a step-down or intensive care unit setting. The role of thrombolysis in submassive PE remains controversial; the PEITHO trial demonstrated that tenecteplase reduced hemodynamic decompensation but increased major bleeding and intracranial hemorrhage compared to anticoagulation alone, leading most guidelines to recommend reserving thrombolysis for submassive PE patients who demonstrate clinical deterioration. Catheter-directed therapy has emerged as an alternative escalation strategy that may provide thrombus reduction with a lower systemic bleeding risk, though randomized controlled trial data remain limited. Serial monitoring of hemodynamics, biomarkers, and clinical status is essential to identify the subset of submassive PE patients who will progress to hemodynamic instability and require escalation of therapy.

Low-risk pulmonary embolism describes hemodynamically stable patients without right ventricular dysfunction or biomarker elevation who have an excellent short-term prognosis with standard anticoagulation therapy alone. A simplified PESI score of 0 identifies patients with a 30-day mortality of approximately 1%, and these patients may be candidates for early discharge or entirely outpatient management if they meet additional criteria. Requirements for outpatient PE treatment include reliable follow-up within one week, adequate social support and understanding of the treatment plan, the ability to obtain and adhere to anticoagulation medications, absence of active bleeding or high bleeding risk, and no additional medical conditions requiring hospitalization. The availability of DOACs with upfront oral dosing, particularly apixaban and rivaroxaban, has greatly facilitated outpatient PE management by eliminating the need for parenteral anticoagulation and INR monitoring.

Venous thromboembolism in pregnancy presents unique diagnostic and therapeutic challenges because the standard approaches are substantially modified by maternal and fetal safety considerations. D-dimer levels are physiologically elevated during pregnancy, limiting the utility of D-dimer testing, though a negative D-dimer in the first trimester may still be useful. Compression ultrasonography remains the first-line imaging study for suspected DVT. For suspected PE, CT-PA is preferred over V/Q scanning by most experts due to its superior diagnostic accuracy, though both expose the fetus to low levels of radiation. Direct oral anticoagulants are absolutely contraindicated in pregnancy due to insufficient safety data and known teratogenicity. Warfarin is teratogenic, particularly during the first trimester, causing warfarin embryopathy. Low-molecular-weight heparin is the treatment of choice throughout pregnancy because it does not cross the placenta. After delivery, patients may be transitioned to warfarin or a DOAC for the postpartum period, with anticoagulation continued for a minimum of 3 months postpartum or a total treatment duration of at least 3 months, whichever is longer.

<image>Panel A: Massive PE treatment algorithm showing systemic thrombolysis with alteplase dosing, contraindications, and alternative interventions including surgical embolectomy, catheter-directed therapy, and ECMO. Panel B: Submassive PE management decision tree showing standard anticoagulation with monitoring and criteria for escalation to thrombolysis or catheter-directed therapy. Panel C: Low-risk PE outpatient management criteria checklist showing simplified PESI score of 0, reliable follow-up, social support, medication access, and absence of bleeding risk or comorbid conditions. Panel D: Pregnancy VTE management flowchart showing diagnostic modifications, LMWH treatment throughout gestation, and postpartum transition options with minimum duration of therapy.</image>

Section 8: Duration of Anticoagulation

The duration of anticoagulation therapy following VTE is one of the most nuanced clinical decisions in internal medicine and is primarily determined by whether the event was provoked or unprovoked and the risk of recurrence versus bleeding. For VTE provoked by a major transient risk factor such as surgery or prolonged immobilization, a treatment duration of 3 months is standard, as the risk of recurrence after completing therapy is low at approximately 3% in the first year. For a first unprovoked VTE, a minimum of 3 months of anticoagulation is required, after which the clinician and patient must decide whether to continue therapy indefinitely. Recurrent unprovoked VTE carries a high recurrence risk estimated at 30 to 50% at 10 years, and indefinite anticoagulation is generally recommended. VTE in the setting of active cancer warrants anticoagulation for the duration of active disease, as the ongoing prothrombotic state of malignancy confers a persistently elevated recurrence risk.

The decision to extend anticoagulation beyond the initial 3-month course requires careful weighing of individual patient factors that influence both recurrence and bleeding risk. Factors favoring extended therapy include male sex, which confers a 50 to 75% higher recurrence risk compared to women, unprovoked presentation, persistently elevated D-dimer after completing the initial treatment course, and residual venous obstruction or persistent right ventricular dysfunction on imaging. Factors favoring discontinuation include provoked VTE, female sex, high bleeding risk, patient preference for stopping therapy, and advanced age with falls risk. The HAS-BLED and VTE-BLEED scores can assist in quantifying bleeding risk, though no single score perfectly captures the complex interplay of factors that determine individual patient risk. Shared decision-making between the clinician and patient, incorporating the patient's values regarding the relative importance of preventing recurrence versus minimizing bleeding risk, is essential for optimal outcomes.

Cancer-associated VTE management has evolved significantly with the demonstration that DOACs offer a viable alternative to LMWH in most cancer patients. Historically, LMWH was the standard of care for cancer-associated VTE based on the CLOT trial demonstrating superiority over warfarin. The HOKUSAI VTE-Cancer and SELECT-D trials subsequently showed that edoxaban and rivaroxaban were noninferior to dalteparin for cancer-associated VTE, leading to updated guidelines recommending DOACs as an acceptable first-line option. However, an important exception exists for patients with gastrointestinal malignancies, in whom DOACs were associated with significantly higher rates of gastrointestinal bleeding, and LMWH remains the preferred agent. Anticoagulation is continued for the duration of active cancer, with periodic reassessment of the benefit-risk balance. Patients with renal impairment may require dose adjustment of LMWH, while DOACs should generally be avoided when creatinine clearance falls below 15 to 30 mL/min depending on the specific agent.

Extended-dose anticoagulation regimens have been developed to optimize the balance between recurrence prevention and bleeding risk during long-term therapy. After completing at least 6 months of full-dose anticoagulation, patients who are continuing therapy may be transitioned to reduced-intensity dosing. Apixaban at 2.5 mg twice daily was evaluated in the AMPLIFY-EXT trial and demonstrated a 67% reduction in recurrent VTE compared to placebo with no significant increase in major bleeding. Rivaroxaban at 10 mg once daily was studied in the EINSTEIN-CHOICE trial and similarly showed significant recurrence reduction without excess major bleeding. These extended-dose regimens provide a practical option for patients in whom indefinite anticoagulation is desired but concerns about long-term bleeding risk are present. The reduced doses are not appropriate for the initial treatment period and should only be initiated after a minimum of 6 months of standard-dose therapy has been completed.

<image>Panel A: Duration of anticoagulation decision framework showing provoked VTE at 3 months, unprovoked first episode at 3 months minimum with extension consideration, recurrent unprovoked at indefinite, and cancer-associated at indefinite during active disease. Panel B: Risk-benefit balance scale showing factors favoring extended therapy on one side and factors favoring stopping therapy on the other with patient preference in the center. Panel C: Cancer-associated VTE treatment timeline showing DOAC or LMWH options with the gastrointestinal malignancy exception and criteria for ongoing therapy assessment. Panel D: Extended-dose anticoagulation regimen comparison showing apixaban 2.5 mg twice daily and rivaroxaban 10 mg daily with trial names, efficacy outcomes, and safety data from AMPLIFY-EXT and EINSTEIN-CHOICE.</image>

Section 9: VTE Prophylaxis

VTE prophylaxis in medical patients requires risk assessment to identify hospitalized patients who would benefit from pharmacologic thromboprophylaxis while avoiding unnecessary bleeding risk in low-risk individuals. Low-risk medical patients who are ambulatory typically require no pharmacologic prophylaxis beyond early and frequent ambulation. Moderate- to high-risk medical patients, including those hospitalized with acute illness, reduced mobility, and additional VTE risk factors, should receive pharmacologic prophylaxis with subcutaneous LMWH, low-dose UFH, or fondaparinux for the duration of hospitalization. In patients with active bleeding or high bleeding risk, mechanical prophylaxis with intermittent pneumatic compression devices provides an alternative that does not increase hemorrhagic complications. Extended post-discharge thromboprophylaxis with rivaroxaban or betrixaban has been studied in acutely ill medical patients, though the benefit-risk balance of extended medical prophylaxis remains less clearly established compared to surgical populations.

Surgical patients warrant VTE prophylaxis tailored to the specific procedure and individual risk factors, with certain high-risk surgeries requiring extended prophylaxis beyond the hospital stay. Major orthopedic surgery, including hip and knee arthroplasty and hip fracture repair, carries the highest VTE risk and requires extended thromboprophylaxis for 28 to 35 days postoperatively. Cancer surgery similarly warrants extended prophylaxis for 28 days, as malignancy creates a persistent prothrombotic state that extends the risk window beyond the immediate postoperative period. General surgical procedures typically require prophylaxis only during hospitalization unless additional risk factors such as malignancy or history of VTE are present. Pharmacologic agents used for surgical prophylaxis include LMWH as the preferred agent for most procedures, fondaparinux for patients with HIT history, and DOACs including rivaroxaban and apixaban approved specifically for prophylaxis after hip and knee replacement.

Mechanical prophylaxis using external compression devices serves as an important adjunct or alternative to pharmacologic prophylaxis depending on the clinical scenario. Intermittent pneumatic compression devices apply cyclic inflation and deflation to the lower extremities, mimicking the muscle pump mechanism to promote venous return and reduce stasis. These devices are recommended for all surgical patients unless contraindicated by lower extremity vascular disease, and they serve as the primary prophylactic modality in patients at high bleeding risk who cannot receive pharmacologic agents. Graduated compression stockings provide a less effective but complementary form of mechanical prophylaxis. In patients at high VTE risk who also have significant bleeding concerns, the combination of mechanical prophylaxis with graduated dose compression and intermittent pneumatic compression may be employed until the bleeding risk has resolved and pharmacologic prophylaxis can be safely initiated.

Special situations in VTE prophylaxis require individualized approaches that account for unique risk profiles and contraindications. Trauma patients are at exceptionally high VTE risk due to the combination of immobility, endothelial injury, and hypercoagulability, and should receive pharmacologic prophylaxis as soon as the bleeding risk is acceptable, typically within 24 to 72 hours of injury. ICU patients should preferentially receive LMWH over unfractionated heparin based on evidence of superior efficacy in this population. Stroke patients require careful assessment because prophylaxis in hemorrhagic stroke must balance VTE prevention against intracranial bleeding risk, while ischemic stroke patients should receive prophylaxis with attention to hemorrhagic transformation risk. Patients with a history of heparin-induced thrombocytopenia must avoid all heparin products, and fondaparinux or a DOAC should be used for prophylaxis. The timing of prophylaxis initiation relative to neuraxial anesthesia requires strict adherence to specific interval guidelines to prevent epidural hematoma.

<image>Panel A: Medical patient VTE prophylaxis algorithm showing risk stratification into low, moderate, and high categories with corresponding prophylaxis recommendations including ambulation, pharmacologic, and mechanical options. Panel B: Surgical VTE prophylaxis duration chart showing extended prophylaxis for hip and knee arthroplasty at 28-35 days, cancer surgery at 28 days, and general surgery for hospital stay duration with agent options. Panel C: Diagrams of mechanical prophylaxis devices including intermittent pneumatic compression and graduated compression stockings with their mechanisms of action and indications. Panel D: Special situations matrix showing trauma, ICU, stroke, and HIT scenarios with their unique VTE prophylaxis considerations and recommended agents.</image>

Section 10: Complications and Special Topics

Heparin-induced thrombocytopenia is a paradoxical prothrombotic complication of heparin therapy that occurs when antibodies form against platelet factor 4 bound to heparin, leading to platelet activation, aggregation, and consumption with a simultaneous increase in thrombin generation. The typical onset is 5 to 14 days after the initiation of heparin therapy, though it may occur earlier in patients with recent prior heparin exposure due to preformed antibodies. The hallmark laboratory finding is a platelet count decline of greater than 50% from baseline or an absolute count below 100,000, though the platelet count rarely falls below 20,000. The clinical paradox of HIT is that despite thrombocytopenia, the predominant complication is thrombosis rather than bleeding, with approximately 50% of untreated patients developing arterial or venous thrombotic events. The 4Ts scoring system provides a pretest probability assessment based on the degree of thrombocytopenia, timing of platelet fall, presence of thrombosis, and absence of other causes, and is validated to identify patients who warrant confirmatory testing with a serotonin release assay or heparin-induced platelet aggregation test. Management requires immediate discontinuation of all heparin products and initiation of a non-heparin anticoagulant such as argatroban, bivalirudin, or fondaparinux.

Post-thrombotic syndrome is the most common long-term complication of deep vein thrombosis, affecting 20 to 50% of patients within 2 years despite adequate anticoagulation therapy. The pathophysiology involves chronic venous hypertension resulting from a combination of persistent venous obstruction by residual thrombus and destruction of venous valves by the inflammatory process accompanying thrombus organization. Clinical manifestations range from mild chronic leg swelling and heaviness to severe complications including chronic pain, skin hyperpigmentation, lipodermatosclerosis, and venous stasis ulceration. Prevention centers on adequate initial anticoagulation to minimize residual thrombus burden, though the SOX trial demonstrated that routine use of graduated compression stockings did not prevent PTS, overturning previous recommendations. Treatment of established PTS is primarily supportive, including leg elevation, exercise, compression therapy for symptom relief, and wound care for venous ulcers. Endovascular interventions including catheter-directed thrombolysis and venous stenting are being investigated for iliofemoral DVT to reduce PTS incidence.

Chronic thromboembolic pulmonary hypertension is an underrecognized complication that occurs in approximately 2 to 4% of patients following acute pulmonary embolism, resulting from incomplete thrombus resolution and progressive fibrotic transformation of organized clot within the pulmonary arteries. Unlike acute PE, in which the thrombus is amenable to anticoagulation and natural fibrinolysis, CTEPH involves organized fibrotic material that is refractory to medical therapy and causes progressive pulmonary vascular remodeling. Patients present with persistent or progressive dyspnea on exertion after an episode of PE, often after an initial period of symptomatic improvement known as the honeymoon period. The diagnostic workup begins with ventilation-perfusion scanning, which is more sensitive than CT-PA for detecting CTEPH, followed by right heart catheterization to confirm pulmonary hypertension and assess hemodynamics. Pulmonary endarterectomy is the definitive treatment for CTEPH and can be curative when performed at experienced centers, while riociguat, a soluble guanylate cyclase stimulator, provides medical therapy for inoperable disease or residual pulmonary hypertension following surgery.

Inferior vena cava filters are mechanical devices placed percutaneously into the IVC to trap emboli migrating from the lower extremity deep veins toward the pulmonary vasculature. The only clearly established indication for IVC filter placement is acute VTE with an absolute contraindication to anticoagulation therapy, such as active major hemorrhage or recent neurosurgical procedure. Retrievable filters, which are designed to be removed once anticoagulation can be safely resumed, are preferred over permanent filters because long-term filter complications include IVC thrombosis, filter migration, filter fracture with embolization of fragments, and paradoxically increased long-term DVT risk due to flow disruption around the filter. IVC filters are not routinely indicated in patients with massive PE, patients with recurrent PE despite adequate anticoagulation, or as prophylactic devices in high-risk patients without established VTE, though clinical judgment may support their use in select cases. When a retrievable filter is placed, proactive follow-up should be established to ensure timely retrieval once anticoagulation is feasible, as many retrievable filters are never removed, leading to avoidable long-term complications.

<image>Panel A: HIT pathophysiology diagram showing heparin-PF4 complex formation, antibody binding, platelet activation and aggregation, and the paradoxical prothrombotic state with the 4Ts scoring criteria. Panel B: Post-thrombotic syndrome progression showing acute DVT, chronic venous obstruction, valve destruction, venous hypertension, and clinical sequelae from edema to venous ulceration with prevention and treatment strategies. Panel C: CTEPH diagnostic pathway from persistent dyspnea after PE through V/Q scan, right heart catheterization, and pulmonary angiography with treatment options including pulmonary endarterectomy and riociguat. Panel D: IVC filter indications and complications showing the single clear indication of anticoagulation contraindication, retrievable versus permanent filter types, and long-term complications including thrombosis, migration, and fracture.</image>

Summary

• VTE encompasses DVT and PE, with pathophysiology explained by Virchow's triad of stasis, endothelial injury, and hypercoagulability
• DVT presents with unilateral leg swelling; use the Wells score to guide D-dimer testing or direct compression ultrasonography
• PE presents with dyspnea and pleuritic pain; use the Wells score and PERC rule to guide D-dimer and CT-PA
• Massive PE with hypotension requires systemic thrombolysis or surgical embolectomy
• Submassive PE with RV dysfunction is managed with anticoagulation and close monitoring, with escalation if deterioration occurs
• DOACs, particularly apixaban and rivaroxaban, are preferred first-line anticoagulants with upfront oral dosing
• Duration of anticoagulation is 3 months for provoked VTE; extended or indefinite for unprovoked or recurrent VTE
• Cancer-associated VTE requires DOAC or LMWH for the duration of active disease, with LMWH preferred for GI malignancy
• VTE prophylaxis includes pharmacologic agents for moderate- to high-risk hospitalized patients and extended prophylaxis for orthopedic and cancer surgery
• HIT is a paradoxical prothrombotic complication requiring immediate heparin cessation and non-heparin anticoagulation

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown